At its meeting on 15 May 2023, the Transparency Council Position No. 52/2023 on the evaluation of Forxiga (dapagliflozin) for the indication: chronic heart failure in adult patients with an ejection fraction LVEF>40%, left ventricular hypertrophy or left atrial enlargement and NT-proBNP levels ≥ 300 pg/ml (or ≥600 pg/ml in patients with atrial fibrillation or atrial flutter) and persistent NYHA class II – IV disease symptoms.